Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma
Interview: Real-world study underscores cabozantinib’s effectiveness as a second-line therapy for mRCC, regardless of prior first-line treatment outcomes.